Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

276.01 -0.71 (-0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 308,468
Open 276.88
Bid (Size) 276.05 (1)
Ask (Size) 285.85 (5)
Prev. Close 276.72
Today's Range 273.28 - 279.26
52wk Range 119.76 - 299.98
Shares Outstanding 17,103,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising. 
Via The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily

Performance

YTD
+21.67%
+21.67%
1 Month
+18.92%
+18.92%
3 Month
+3.89%
+3.89%
6 Month
+19.55%
+19.55%
1 Year
+12.44%
+12.44%

More News

Read More
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Via The Motley Fool
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Via The Motley Fool
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Is Madrigal Pharmaceuticals Stock a Buy?
Via The Motley Fool
2 Under-the-Radar Growth Stocks to Consider
Via The Motley Fool
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Via The Motley Fool
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Via Investor's Business Daily
1 No-Brainer Growth Stock to Buy Now
Via The Motley Fool
The Week Ahead: What's Next
Via Talk Markets
MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
6 Stocks Positioned to Soar as Investors Focus on MASH
Via TheNewswire.com
7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024
Via InvestorPlace
Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in April 2024
Via InvestorPlace
2 Top Biotech Buyout Candidates
Via Talk Markets
Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals
Via The Motley Fool
Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.